Jasper Therapeutics/JSPR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Jasper Therapeutics

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU). It also has ongoing programs in diseases where targeting diseased hemopoietic stem cells can provide benefits, such as Lower to Intermediate Risk Myelodysplastic Syndrome (LR-MDS), and stem cell transplant conditioning regimens. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.

Ticker

JSPR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Ronald Martell

Employees

45

Headquarters

Redwood city, United States

JSPR Metrics

BasicAdvanced
$392M
Market cap
-
P/E ratio
-$5.60
EPS
2.25
Beta
-
Dividend rate
$392M
2.24928
$31.01
$4.00
94K
13.493
-48.30%
-53.63%
-51.58%
3.459
3.459
50.54%

What the Analysts think about JSPR

Analyst Ratings

Majority rating from 8 analysts.
Buy

JSPR Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$14M
-16.97%
Profit margin
0.00%
NaN%

JSPR Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 15.92%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.50
-$1.60
-$1.50
-$1.03
-
Expected
-$1.50
-$1.55
-$1.62
-$1.23
-$1.09
Surprise
0.13%
3.06%
-7.12%
-15.92%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Jasper Therapeutics stock?

Jasper Therapeutics (JSPR) has a market cap of $392M as of June 15, 2024.

What is the P/E ratio for Jasper Therapeutics stock?

The price to earnings (P/E) ratio for Jasper Therapeutics (JSPR) stock is 0 as of June 15, 2024.

Does Jasper Therapeutics stock pay dividends?

No, Jasper Therapeutics (JSPR) stock does not pay dividends to its shareholders as of June 15, 2024.

When is the next Jasper Therapeutics dividend payment date?

Jasper Therapeutics (JSPR) stock does not pay dividends to its shareholders.

What is the beta indicator for Jasper Therapeutics?

Jasper Therapeutics (JSPR) has a beta rating of 2.25. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Jasper Therapeutics stock price target?

The target price for Jasper Therapeutics (JSPR) stock is $67, which is NaN% below the current price of $. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Jasper Therapeutics stock

Buy or sell Jasper Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing